Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer

By sjmartinez • October 22, 2022

Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Di Lorenzo G, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. BJU Int. 2022 Nov;130(5):592-603. doi: 10.1111/bju.15603. Epub 2021 Oct 25. PMID: 34597472.

Tags: BladderCancer, blcsm, Hematology/Oncology, immune checkpoint, immunotherapy, inhibitors, Outcomes, Publications, urinary tract neoplasms, uroonc, urothelial carcinoma, utuc

Do All Breast Cancer Survivors Need to See a Cardiologist?

Ganz PA, Yang EH. Do All Breast Cancer Survivors Need to See a Cardiologist? JAMA Oncol. 2025 Oct 23. doi: 10.1001/jamaoncol.2025.4141. Epub ahead of print.[...]

Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial

Hecht JR, Park YS, Tabernero J, Lee MA, Lee S, Virgili AC, Van den Eynde M, Fontana E, Fakih M, Asghari G, So J, Stein[...]

Analyses of adverse events and patient-reported outcomes with the toxicity index in cancer clinical trials

Gresham G, Henry NL, Bandos H, Calsavara VF, Cecchini RS, Diniz MA, Hays RD, Luu M, Kim S, Rogatko A, Yothers G, Ganz PA, Tighiouart[...]